A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Author Index

A

Albiges, Laurence
Complete Remission is a Reachable Goal in mRCC

Arrighi, Nicola
Surgical Treatment of Atypical Metastases from RCC

B

Bellmunt, Joaquim
Complete Remission is a Reachable Goal in mRCC

Beuselinck, Benoit
Inflammation in mRCC: Target or Prognostic Factor?

Bracarda, Sergio
Rare Complications of Systemic mRCC Treatment

Bukowski, Ronald M.
Setting the Scene: Current Status of Surgical and Medical mRCC-Treatment

C

Calabro, Fabio
Pazopanib is the Best Choice in First-Line

Calvo, Emiliano
Management of Collecting Duct Carcinoma and Case

Csaba, Pustzai
Cases Presentation

E

Eisen, Tim
Are Currently Available mTOR-Inhibitors Convincing in mRCC?

Rationale for Anti-VEGF(R)-Strategies in the Adjuvant Setting: Is There a Target at All?

Escudier, Bernard
Strategies Beyond VEGF-Inhibitors and mTOR-Inhibitors

F

Fisher, Rosalie
Case 2: Success in mRCC

mRCC Poor Risk Long-Term Survivor: Case 3

G

Géczi, Lászlo
Welcome

Gore, Martin
Second-Line Strategies

Grünwald, Viktor
What can we Expect from Running Phase III Trials: Will all of Them Alter the Current Treatment Algorithm?

J

Jonasch, Eric
Depressive Symptoms as Key Predictors of Survival in mRCC

K

Khoo, Vincent
What Should we Do About Patients with Brain Metastases?

Kollmannsberger, Christian
Management of Chronic Renal Failure Under Anti-VEGF-Directed Treatment

L

Larkin, James
The Cytokine-Era is Over: What Should We Do About Sorafenib?

M

McDermott, David F.
Novel Immunotherapeutic Approaches in mRCC

Méjean, Arnaud
Cases Presentation

Melichar, Bohuslav
Bevacizumab+Low Dose IFN is the Best Choice in First-Line

Mickisch, Gerald
Rare Metastatic Sites in mRCC: A Different Disease?

Small Primary in Metastatic Disease: Is it Worth to be Removed? PRO

Moch, Holger
Pathology of RCC: What do Clinicians Need to Know

N

Nathan, Paul
Metabolic Disorders

Negrier, Sylvie
Case 1: Success in mRCC (with an Unusual Strategy)

mRCC Intermediate Risk Long-Term Survivor: Case 2

P

Patard, Jean Jacques
Debate: Lymphadenectomy is Important in mRCC—CON

Small Primary in Metastatic Disease: Is it Worth to be Removed? CON

Porta, Camillo
Sunitinib Remains the Best Choice in First-Line

Procopio, Giuseppe
Case(s): How to Deal with Mixed Response

Powles, Thomas
Management of Papillary Type 2 mRCC and Case and Study

R

Ravaud, Alain
EGFR-Targeting in mRCC: A Closed Chapter?

S

Schmidinger, Manuela
What Does the Medical Oncologist Expect from the Surgeon Including Case (and Metastasectomy)

Mechanisms and Management of Diarrhea from Anti-VEGFR-TKIs

Sternberg, Cora N.
Management of Translocational Tumors and Case and Study

Szczylik, Cesary
mRCC-Favorable Risk Long-Term Survivor: Case 1

T

Tenke, Peter
Cases Presentation

W

Wood, Christopher G.
Debate: Lymphadenectomy is Important in mRCC PRO